Loading…
LOANS for Biomedical Research Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
1d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Long-term Opportunities for Advancing New Studies for Biomedical Research Act or the LOANS for Biomedical Research Act This bill requires the Department of Health and Human Services (HHS), in consultation with the Department of the Treasury, to establish the Biobonds Program to support loans for clinical trials for eligible drugs and medical devices. Specifically, Treasury must contract with institutions to act as fiscal agents to carry out the program. Fiscal agents must (1) purchase loans made to borrowers engaged in eligible biomedical research activities, and (2) sell bonds comprised of such loans. HHS shall guarantee a portion of the bond payments. An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device. HHS must issue rules relating to various aspects of the program, including rules concerning (1) which loans should be prioritized for purchase, (2) the terms and conditions of the loans, and (3) the size of each bond issuance. Treasury must issue rules relating to the program's underwriting practices and compensation for the fiscal agents. The Government Accountability Office must periodically report to Congress on the program, including an analysis of the risk to the government in guaranteeing the bonds.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2022 · fourth_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act.
Client expense: Not reported · Firm income: Not reported
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medical/Disease Research/Clinical Labs
Seek approval for regulatory support; HR3437; Loans Act.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Medical/Disease Research/Clinical Labs
seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Medical/Disease Research/Clinical Labs
seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
HR 5776, the Build Back Better Act; S 466, Protecting Americans with Pre-existing Conditions Act; S 1002, The Junk Plan Accountability and Disclosure (JPADA) Act; HR 1875, PHA Amendment Re: STLDI; HR 369, the Health Care Affordability Act; HR 892, Pre-Existing Conditions Protection Act of 2021; HR 1872, MORE Health Education Act; HR 1890, Network Adequacy Standards for QHPs; HR 1896, State Allowance for Variety of Exchanges Act; HR 1887, State Health Care Premium Reduction Act of 2021; HR 1790, Fair Indexing for Health Care Affordability; HR 1390, CHIPPER Act; HR 1791, CHIP Permanency Act; S. 464/H.R. 2163, the Safe Step Act; HR 3437, the LOANS for Biomedical Research Act; HR 4385 / S 3080, the Cancer Drug Parity Act; HR 5030 / S 2706, the Diverse Act; HR 942, the No Junk Plans Act reforms promoting racial and socioeconomic diversity in clinical trials; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of association health plans and other non-ACA compliant insurance plans; implementation of the No Surprises Act (enacted in the 116th Congress); federal regulation of junk insurance plans;
Client expense: $175,000 · Firm income: Not reported
2021 · fourth_quarter · Medical/Disease Research/Clinical Labs
seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
S 466, Protecting Americans with Pre-existing Conditions Act; S 1002, The Junk Plan Accountability and Disclosure (JPADA) Act; HR 1875, PHA Amendment Re: STLDI; HR 369, the Health Care Affordability Act; HR 892, Pre-Existing Conditions Protection Act of 2021; HR 1872, MORE Health Education Act; HR 1890, Network Adequacy Standards for QHPs; HR 1896, State Allowance for Variety of Exchanges Act; HR 1887, State Health Care Premium Reduction Act of 2021; HR 1790, Fair Indexing for Health Care Affordability; HR 1390, CHIPPER Act; HR 1791, CHIP Permanency Act; S. 464/H.R. 2163, the Safe Step Act; HR 3437, the LOANS for Biomedical Research Act; HR 4385, the Cancer Drug Parity Act; HR 5030, the Diverse Act; HR 942, the No Junk Plans Act reforms promoting racial and socioeconomic diversity in clinical trials; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of association health plans and other non-ACA compliant insurance plans; implementation of the No Surprises Act (enacted in the 116th Congress); federal regulation of junk insurance plans; Consumer Assistance Programs
Client expense: $140,000 · Firm income: Not reported
2021 · third_quarter · Health Issues
S. 289/H.R. 869 - RISE Act of 2021 Issues related to prescription drug pricing, particularly as it relates to insulin Issues and legislation related to providing (during the COVID-19 emergency period) and preserving (post the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes Issues related to the creation of the Advanced Research Projects Agency for Health (ARPA-H) H.R. 3437 Long-term Opportunities for Advancing New Studies (LOANS) for Biomedical Research Act
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Budget/Appropriations
Seek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Medical/Disease Research/Clinical Labs
eek approval for regulatory support; HR3437; Loans Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
S 466, Protecting Americans with Pre-existing Conditions Act; S 1002, The Junk Plan Accountability and Disclosure (JPADA) Act; HR 1875, PHA Amendment Re: STLDI; HR 369, the Health Care Affordability Act; HR 892, Pre-Existing Conditions Protection Act of 2021; HR 1872, MORE Health Education Act; HR 1890, Network Adequacy Standards for QHPs; HR 1896, State Allowance for Variety of Exchanges Act; HR 1887, State Health Care Premium Reduction Act of 2021; HR 1790, Fair Indexing for Health Care Affordability; S 245, the States Achieve Medicaid Expansion Act (aka SAME Act); HR 1390, CHIPPER Act; HR 1791, CHIP Permanency Act; HR 1738, Stabilize Medicaid and CHIP Coverage Act; HR 340, Incentivizing Medicaid Expansion Act; S. 464/H.R. 2163, the Safe Step Act; HR 3437, the LOANS for Biomedical Research Act; reforms promoting racial and socioeconomic diversity in clinical trials; FDA regulations regarding sites of delivery for clinical trial services; federal regulation of association health plans; federal regulation of employer-provided health benefit plans; implementation of the No Surprises Act (enacted in the 116th Congress); the Cancer Drug Parity Act (not yet introduced); the No Junk Plans Act (not yet introduced); federal regulation of junk insurance plans Consumer Assistance Programs
Client expense: $250,000 · Firm income: Not reported
2021 · second_quarter · Health Issues
S. 289/H.R. 869 - RISE Act of 2021 Issues related to drug pricing, particularly as it relates to insulin Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions Issues and legislation related to providing (during the COVID-19 emergency period) and preserving (post the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes Issues related to surprise medical billing H.R. 3437 Long-term Opportunities for Advancing New Studies (LOANS) for Biomedical Research Act S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
H.R. 3437, LOANS for Biomedical Research Act, all provisions H.R. 3824/S.2065. Supplemental Security Income Restoration Act of 2021, all provisions H.R. 4003/S.2108, Work Without Worry Act, all provisions H.R. 4160, Global Autism Act, all provisions H.R. 4131, a bill to expand access to homes and community-based services, all provisions S.2210, Better Care Better Jobs Act, all provisions Implementation of 1905(r) of the Social Security Act, provisions related to early and periodic screening, diagnostic, and treatment services. Implementation of Public Law No. 114-255, 21st Century Cures Act, provisions related to Electronic Visit Verification Implementation of Public Law No. 116-260, Consolidated Appropriations Act, 2021, provisions related to USAID autism programs Implementation of Public Law No. 116-60, Autism Collaboration, Research, Education, and Support Act of 2019, all provisions Implementation of Public Law No. 117-2, American Rescue Plan Act of 2021, provisions related to home and community-based services, special education funding, and economic impact payments for dependents over age 16 ABLE Employment Flexibility Act, a bill not yet introduced to allow employers to contribute to ABLE accounts in lieu of retirement plan contributions Cures 2.0 Act, a bill not yet introduced to continue the acceleration of the discovery, development, and delivery of 21st century cures A bill not yet introduced to reauthorize the Workforce Innovation Opportunity Act A bill not yet introduced for improved autism services A bill not yet introduced to improve coverage of autism services under TRICARE A bill not yet introduced making appropriations for Fiscal Year 2022 for the Department of Defense, provisions related to the Congressionally Directed Medical Research Program Autism Research Program A bill not yet introduced making appropriations for Fiscal Year 2022 for the Departments of Labor, Health and Human Services, and Education, and related agencies, provisions related to autism funding at National Institutes of Health, Centers for Disease Control and Prevention, and the Health Resources and Services Administration A bill not yet introduced making appropriations for Fiscal Year 2022 for the Departments of Commerce and Justice, Science, and Related Agencies, provisions related to the Kevin and Avontes Law program
| Republican |
| PA |
| Danny K. Davis | Democratic | IL |
| Deborah K. Ross | Democratic | NC |
| G. K. Butterfield | Democratic | NC |
| Jake Auchincloss | Democratic | MA |
| Jared Huffman | Democratic | CA |
| Jim Cooper | Democratic | TN |
| John H. Rutherford | Republican | FL |
| Josh Gottheimer | Democratic | NJ |
| Michael F. Doyle | Democratic | PA |
| Mike Levin | Democratic | CA |
| Raúl M. Grijalva | Democratic | AZ |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Steve Cohen | Democratic | TN |
| Terri A. Sewell | Democratic | AL |
| Tom O’Halleran | Democratic | AZ |
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Client expense: $90,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, Labor, Dept of (DOL), Natl Institute of Mental Health (NIMH), SENATE, U.S. Agency for International Development (USAID), White House Office